PMID- 36300335
OWN - NLM
STAT- MEDLINE
DCOM- 20230612
LR  - 20230612
IS  - 2295-3337 (Electronic)
IS  - 1784-3286 (Linking)
VI  - 78
IP  - 4
DP  - 2023 Aug
TI  - Ectodysplasin A is associated with the presence and severity of coronary artery 
      disease and poor long-term clinical outcome in patients presenting with 
      ST-elevation myocardial infarction.
PG  - 270-279
LID - 10.1080/17843286.2022.2140246 [doi]
AB  - OBJECTIVES: Hepatokines are proteins secreted by hepatocytes and many hepatokines 
      such as fetuin A/B, selenoprotein P have been shown to play a role in the 
      pathogenesis of many metabolic dysfunctions such as diabetes, insulin resistance, 
      hypertension, and metabolic syndrome by showing autocrine, paracrine and systemic 
      effects. Ectodysplasin A (EDA) is a recently discovered hepatokine that plays a 
      role in the development of ectodermal structures. In recent studies, it has been 
      revealed that EDA may be associated with the pathogenesis of non-alcoholic liver 
      disease, insulin resistance, Type 2 diabetes mellitus. The close relationship 
      between these metabolic diseases and coronary artery disease (CAD), which may be 
      associated with insulin resistance, has been well documented in previous studies. 
      However, until now, there is no study examining the relationship of EDA with CAD 
      and its effect on long-term outcomes. In this study, we aim to reveal this 
      relationship on patients presenting with ST elevation myocardial infarction 
      (STEMI). METHODS: EDA levels of 544 patients who applied to the study with STEMI 
      and 544 people without coronary artery disease were included in the control 
      group, and the patients with STEMI were followed for median of 33.7 +/- 6.8 months. 
      RESULTS: We found that EDA levels were significantly higher in patients with 
      STEMI and that EDA levels were proportional to the severity of CAD (p < 0.001) 
      also EDA levels may be an independent predictor of poor clinical outcome in 
      patients with STEMI. CONCLUSION: These results suggest that EDA is closely 
      related to the presence and severity of CAD.
FAU - Toprak, Kenan
AU  - Toprak K
AUID- ORCID: 0000-0001-8923-8709
AD  - Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, 
      Turkey.
FAU - Kaplangoray, Mustafa
AU  - Kaplangoray M
AD  - Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey.
FAU - Palice, Ali
AU  - Palice A
AD  - Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey.
FAU - Tascanov, Mustafa Begenc
AU  - Tascanov MB
AD  - Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, 
      Turkey.
FAU - Altiparmak, Ibrahim Halil
AU  - Altiparmak IH
AD  - Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, 
      Turkey.
FAU - Bicer, Asuman
AU  - Bicer A
AD  - Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, 
      Turkey.
FAU - Demirbag, Recep
AU  - Demirbag R
AD  - Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, 
      Turkey.
LA  - eng
PT  - Journal Article
DEP - 20221027
PL  - England
TA  - Acta Clin Belg
JT  - Acta clinica Belgica
JID - 0370306
RN  - 0 (Ectodysplasins)
SB  - IM
MH  - Humans
MH  - *Coronary Artery Disease/complications
MH  - *ST Elevation Myocardial Infarction/complications
MH  - Ectodysplasins
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Insulin Resistance
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Ectodysplasin A
OT  - Hepatokine
OT  - Long-term clinical outcome
OT  - ST elevation myocardial infarction
OT  - coronary artery disease
EDAT- 2022/10/28 06:00
MHDA- 2023/06/12 06:42
CRDT- 2022/10/27 04:22
PHST- 2023/06/12 06:42 [medline]
PHST- 2022/10/28 06:00 [pubmed]
PHST- 2022/10/27 04:22 [entrez]
AID - 10.1080/17843286.2022.2140246 [doi]
PST - ppublish
SO  - Acta Clin Belg. 2023 Aug;78(4):270-279. doi: 10.1080/17843286.2022.2140246. Epub 
      2022 Oct 27.